Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  bexarotene
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 31 for your search:
Start Over
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7273-G000-401, NCT01007448
Phase II/III Randomized Study of High-Dose vs Moderate-Dose LGD1069 vs Placebo in Advanced non-Small Cell Lung Cancer (Summary Last Modified 08/98)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-20, NCI-V96-1050
Phase II/III Study of Targretin (LGD1069) Capsules in Patients with Refractory or Recurrent Early Stage T-Cell Lymphomas (Summary Last Modified 05/1999)
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-23, NCI-V97-1149
Phase II/III Evaluation of Targretin Capsules in Patients with Refractory Advanced Stage Cutaneous T-Cell Lymphoma (Summary Last Modified 11/98)
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-24, NCI-V97-1151
Phase III Study of Targretin (LGD1069) Topical Gel in Patients with Refractory or Persistent Early Stage Cutaneous T-Cell Lymphoma (Summary Last Modified 12/98)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069T-25, NCI-V97-1292
Phase III Randomized Study of Cisplatin and Vinorelbine With or Without Bexarotene in Patients With Chemotherapy-Naive Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-49
Phase III Randomized Study of Carboplatin and Paclitaxel With Bexarotene Versus Carboplatin and Paclitaxel Alone in Patients With Chemotherapy-Naive Stage IIIB or IV Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-48, BMC-C-7093-49, UCLA-0301086
Phase I/II Pilot Study of Topical LGD1069 (a Selective Retinoid) for Cutaneous T-Cell Lymphoma (Summary Last Modified 09/98)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Other
Protocol IDs: MDA-DM-94098, NCI-V95-0621
Phase I/II Multicenter Study of Combination Therapy With LGD1069 Oral Capsules (Targretin) and Interferon Alfa-2b (Intron A) in Patients With Advanced Renal Cell Carcinoma (Summary Last Modified 12/98)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: UCLA-HSPC-960630001, LIGAND-L1069-17, LIGAND-UCLA-HSPC-960630001, NCI-V97-1205
Phase II Study of Oral LGD1069 plus IFN-A for Metastatic Renal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: YALE-HIC-8644, LIGAND-YALE-HIC-8644, NCI-V96-0882
Phase II Study of Oral LGD1069 (a Synthetic Retinoid Analogue) for AIDS-Related Kaposi's Sarcoma (Summary Last Modified 07/98)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-21, NCI-V96-0973
Phase II Study of Targretin (LGD1069) Capsules in Metastatic Androgen Independant Prostate Cancer (Summary Last Modified 05/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1069-22, NCI-V97-1124
A Multicenter Phase II Evaluation of Targretin Capsules (LGD 1069) in Asymtomatic Patients with Ovarian Cancer Now with an Elevated Serum CA 125 Following Complete Remission (Summary Last Modified 12/98)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-96061, LIGAND-MSKCC-96061, NCI-G97-1140
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: D-0440, NCT00125359
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 050416, NCT00178841
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 05-098, MSKCC-05098, NCT00255801
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: J0675 CDR0000525989, P30CA006973, JHOC-J0675, JHOC-NA_00003076, J0675, NCT00425477
BATTLE Program: Tarceva and Targretin in Patients With NSCLC
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0826, NCI-2012-02089, W81XWH-06-1-0303, NCT00411632
Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 04407, NCT00615784
Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL/06/009, CRUK-UCL-GEMBEX, EU-20841, EUDRACT 2006-000591-33, NCT00660231
Phase I Study of Daily Oral LGD1069 for Advanced, Recurrent Squamous Cell Cancer of the Head and Neck (Summary Last Modified 06/98)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: Other
Protocol IDs: MDA-DM-94045, NCI-V94-0497
Start Over